Product Description
Desloratadine is used in adults and children to relieve hay fever and allergy symptoms, including sneezing; runny nose; and red, itchy, tearing eyes. It is also used to relieve symptoms of urticaria (hives; red, itchy raised areas of the skin), including itching and rash. Desloratadine is in a class of medications called antihistamines. It works by blocking histamine, a substance in the body that causes allergic symptoms. (Sourced from: https://medlineplus.gov/druginfo/meds/a602002.html)
Mechanisms of Action: H1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Organon
Company Location: JERSEY CITY NJ 07302
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Brazil, China, Germany
Active Clinical Trial Count: 8
Highest Development Phases
Phase 3: Conjunctivitis, Allergic|Environmental Hypersensitivity|Rhinitis, Allergic|Rhinitis, Allergic, Perennial|Urticaria
Phase 2: Dust mite Hypersensitivity|Grass Pollen Hypersensitivity|Inflammation|Sneezing
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| T502-SIT-073 | P3 |
Unknown Status |
Conjunctivitis, Allergic|Rhinitis, Allergic |
2025-06-13 |
|
| DESPRED | P3 |
Recruiting |
Rhinitis, Allergic |
2025-05-30 |
|
| CTR20221696 | P1 |
Completed |
Urticaria|Rhinitis, Allergic |
2022-08-15 |
|
| A Phase III clinical trial of MK-4117 in Japanese subjects with chronic urticaria | P3 |
Active, not recruiting |
Urticaria|Environmental Hypersensitivity |
2021-07-24 |